AtheroMed said it’s raised a $6 million equity round, taking its total funding raise since 2009 to $20 million, according to regulatory filings.
The Menlo Park, Calif.-based medical device company is developing an atherectomy device for treating peripheral artery disease, according to its website.
AtheroMed is still flying under the radar, to judge by the 1-page website, which provides only an email link to contact the company.
AtheroMed did not immediately respond to an email sent to that address.
The filing for AtheroMed’s most recent $6 million round lists 4 venture capitalists and a pair of executive officers, president Mike MacKinnon and founder and chief technology officer Chris Danek. The VC players named are Tony Chou, a general partner at Vertical Group; Alan Kaganov, a partner with U.S. Venture Partners, and Casey Tansey, a GP there; and David Schulte of Chilmark Partners and Kaiser Permanente Ventures.
AtheroMed has reported raising a total of $20 million since October 2009, according to the filings.
The company raised $2.4 million of a hoped-for $10.5 million that month, according to the filings. In May 2011, AtheroMed reported raising another $7.5 million (of a hoped-for $8 million round). Nearly a year later, in March 2012, AtheroMed pulled in all of a hoped-for $4.5 million round.
